SynBioCon 大会 | 生物制造青年论坛 特色专场 生物制造青年论坛 8月20日，浙江·宁波 生物制造领域有哪些 "潜力股" 团队、技术和产品值 得关注？ 为发掘合成生物学和生物制造科研团队创新成果、 促进生物制造领域优秀科研工作者成果交流和产业方对接， 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2025 ) 同期将举办特色专场——" 生物制造青年论坛 "，于8月20日在浙江宁波举办。 助力行业 15分钟了解一个方向 ，重点阐述研究领域存在的科学问题、解决思路、成果、放大可行性以及未来发展方向。 欢迎高校、科研院所申报分享！ 扫码报名，请选择参会形式 报名请选择：青年论坛、科技成果展示 SynBioCon 2 025 8月20-22日，浙江·宁波 01 论坛信息 时 间： 8月20日（周三） 席 位 ： 仅 30 席！ 报告时间： 第一场：13:30-17:30； 第二场：19:00-20:30 报名须知 ：扫描以上二维码，会务组将第一时间与您确认，并对接报告信息表等； 02 科技成果展示与对接专场 （同期活动） SynBioCon 2025 将设置 「科技成果展示与对接」专场 （ ...

精英计划-人才需求 | 天津工生所 中国科学院天津工业生物技术研究所是由中国科学院与天津市人民政府共建、整建制从事生物制造和 工业生物技术研究的国立科研机构，是我国工业生物领域的战略科技力量，肩负着创新生物产业关键 核心技术、发展生物制造重大颠覆性技术、支撑我国生物经济高质量可持续发展的历史使命，围 绕"以可再生碳资源替代化石资源、以清洁生物加工方式替代传统化学加工方式、以现代生物技术提 升产业水平"三大战略主题，重点开展"工业蛋白质科学与生物催化工程、合成生物学与微生物制造 工程、生物系统与生物工艺工程"三个领域方向的基础研究和应用基础研究。 招 聘部门 简介 01 邓子新大师工作室以活性天然产物的创新与绿色制造为目标，遵循"师从于自然、认知于自然，创新 于自然"的学术思路，运用合成生物学理念，聚焦交叉学科前沿，建立和完善天然药物精准发掘、结 构创新和优产新模式，实现微生物天然药物的高效生产。 团队由 徐敏研究员 与 侯安伟研究员 领衔，重点关注全新作用机制抗生素（糖肽抗生素）与萜类天 然产物的高效精准挖掘、生物合成机制与作用机制解析以及相关新分子的高效创制。 徐敏研究员主要从事微生物天然产物合成生物学以及 ...

6月20日，工业和信息化部党组书记、部长李乐成主持召开第十次中小企业圆桌会议。会上，来自量子 科技、人工智能、人形机器人、生物制造等未来产业领域的10家初创期中小企业负责人介绍了技术研 发、人才引育、投融资支持、场景应用等方面情况，结合各自生产经营中遇到的困难和挑战，提出政策 举措建议。李乐成强调，我国中小企业有灵气、有活力，发展未来产业前景广阔、大有可为。希望大家 树立雄心壮志，加强前沿技术和颠覆性技术突破，打造原创技术策源地，加快产出标志性产品、形成引 领性标准。要坚持走专精特新发展道路，聚焦细分领域苦练内功，不断提高企业质量、效益和核心竞争 力。要大力弘扬企业家精神，坚定发展信心，保持战略定力，用足用好国家各类支持政策，乘势而上， 当好前行者、开拓者，为发展新质生产力、推进新型工业化积极贡献力量。(工信微报) ...

Core Viewpoint - The company reported a significant increase in overseas revenue for 2024, driven primarily by the growth in amino acid product sales and the introduction of new products, despite a decline in overall gross margin due to competitive pricing pressures in the market [2][18]. Group 1: Overseas Revenue Performance - The company achieved overseas revenue of 1.032 billion yuan in 2024, accounting for 47.39% of total revenue, representing a year-on-year growth of 30.34% [2][3]. - The main contributors to the overseas revenue growth were the amino acid series products, particularly L-valine, and the vitamin series products, which saw increased sales volumes [5][18]. - The company’s overseas sales were primarily concentrated in Europe (41.58%), the Americas (28.51%), and Asia & others (29.91%) [3][4]. Group 2: Gross Margin Analysis - The overall gross margin for the company in 2024 was reported at 24.92%, a decrease of 15.60 percentage points compared to the previous year [18]. - The gross margin for amino acid products was 30.00%, down 13.32 percentage points, while the vitamin products experienced a more significant decline [18][19]. - The decline in gross margin was attributed to lower average selling prices for key products such as L-valine and myo-inositol, which saw price drops of 17.89% and 54.09% respectively [19][20]. Group 3: Future Outlook and Industry Trends - The demand for amino acids is expected to continue growing due to trends in precision nutrition and the reduction of traditional feed ingredients like soybean meal [23][24]. - The global market for biosynthetic vitamins is projected to grow significantly, with a compound annual growth rate of 9.32% from 2024 to 2030, driven by advancements in synthetic biology [24]. - The company is positioned to benefit from its technological advantages in fermentation processes, which are more environmentally friendly and cost-effective compared to traditional methods [27][28].

第二届合成生物学与生物制造应用大会 九大活动精彩安排 | | 第二届合成生物学与生物制造应用大会 日程安排 | | --- | --- | | 6月19日 上午 | 开幕+主题报告 | | 6月19日 下午 | 未来食品与功效物质开发智造智用专题 | | 6月19日 下午 | SCC细胞健康产业专题 | | 6月20日 上午 | AI+合成生物制造创新发展专题 | | 6月20日 上午 | 精准开发与产业创新专题 | | 6月20日 上午 | 生物医药产业专题暨留・在光明-光明留学人员嘉年华 | | 6月20日 下午 | 大健康与美妆产业智造智用专题 | | 6月20日 下午 | 传统产业与新生物制造交叉创新专题 | | 6月20日 下午 | 创新项目投融资路演 | 免费报名通道 第二届合成生物学与生物制造应用大会 时间: 2025年6月19-20日 上 午 9:00-18:00 地点: 中国·深圳·光明区·卫光生命科学园一楼学术报告厅（导航：卫光生命科学园） 扫码免费报名参会 详细会议流程 大咖嘉宾6月19-20日 相约鹏城 育成绩 物理 www.ziang with and and and and and ...

Core Viewpoint - The article emphasizes the development of the biomanufacturing industry in Hubei Province, which is seen as a key future industry as outlined in the 2025 government work report, aiming to transform small microorganisms into large-scale industries [1]. Group 1: Agricultural Biomanufacturing - Hubei Fubon Technology Co., Ltd. is focusing on innovative agricultural biopreparations, developing new biodegradable coating agents and soil restoration agents to enhance grain yield [2]. - The company's core product, "biostimulants," acts as a "lubricant" and "amplifier" in agricultural production, improving the efficiency of pesticides and fertilizers [4]. - The research team led by Professor Chen Shouwen from Hubei University has developed a biostimulant using Bacillus licheniformis, showcasing advantages in bioprocessing and broad applications [4]. Group 2: Industrial Microbial Strains - Industrial microbial strains are considered the "chips" of biomanufacturing, with over 80% of core industrial strains in China being dependent on foreign sources [6]. - Research on the strain "Pseudomonas putida" has shown its potential to convert agricultural waste into ethanol, presenting a sustainable alternative to traditional methods that rely on food crops [8]. - Wuhan Ruijia Kang Biotechnology Co., Ltd., founded by Professor Yang Shihui, has developed cellulose ethanol and D-lactic acid, with plans to achieve a production scale of 100,000 tons within five years [8]. Group 3: Collaborative Innovation - Hubei Province is building a collaborative system involving government, industry, academia, and finance to accelerate the development of biomanufacturing [9]. - Hubei University has established partnerships with companies like Angel Yeast to create a joint innovation platform for synthetic biology and modern biomanufacturing [10]. - The provincial government is addressing technology demands across various sectors to promote high-quality development in the synthetic biology industry during the 14th Five-Year Plan [12].

Core Insights - The recent breakthrough in AI enzyme design by MoleculeMind and Hong Kong Polytechnic University has been recognized at the ICML 2025 conference, marking a significant advancement in the field of AI enzyme design [1] - The traditional methods of enzyme discovery and optimization are time-consuming and costly, with a success rate of less than 1%, highlighting the urgent need for innovative solutions in the biomanufacturing sector [2] - The introduction of the SENZ method, which utilizes substrate structure similarity for enzyme design, represents a novel approach that could revolutionize enzyme generation [3][5] Industry Overview - Enzymes are crucial for the development of the trillion-dollar bio-economy, impacting sectors such as biomedicine, green chemistry, and environmental degradation [1] - The lack of ideal biocatalysts is a major barrier to scaling production in the biomanufacturing industry, leading to annual capacity losses exceeding $100 billion in pharmaceuticals, chemicals, and agriculture [2] - AI protein design has emerged as a promising solution to generate precise catalysts by learning from existing enzyme structure-function relationships, although it faces challenges with novel synthetic molecules due to limited training data [2] Company Developments - MoleculeMind has developed the SENZ method, which integrates biological data retrieval and generative AI to create enzymes without direct catalytic data, thus addressing a critical challenge in enzyme generation [3][5] - The SENZ method has demonstrated superior performance compared to traditional enzyme design methods, potentially providing tailored solutions for complex drug synthesis and environmental remediation [6] - MoleculeMind is expanding its capabilities in "on-demand design" across various fields, including antibodies, vaccines, and industrial enzymes, aiming to provide innovative biological solutions for health, environmental, and sustainability challenges [7]

Group 1 - The China Securities Regulatory Commission (CSRC) released eight measures to deepen the reform of the Sci-Tech Innovation Board, aiming to enhance the development of new productivity and promote the board as a "testing ground" for innovation [1] - The measures include reforms in issuance and underwriting, equity and debt financing, mergers and acquisitions, and trading mechanisms, with a focus on increasing institutional inclusiveness and adaptability [1] Group 2 - The Ministry of Industry and Information Technology and the National Development and Reform Commission aim to cultivate over 20 pilot platforms for biomanufacturing by 2027, facilitating the scale-up of the industry [2] - Significant technological breakthroughs and industry developments are occurring in biomanufacturing, with companies like Kasei Biotech and Jinbo Biotech increasing their investments [2] Group 3 - The automotive industry is seeing an acceleration in the international expansion of autonomous driving companies, with new guidelines for data export safety being proposed [3] - The guidelines require safety assessments for various data types related to vehicle operation, road environments, and personal privacy [3] Group 4 - The Ministry of Human Resources and Social Security reported that the accumulated fund size of enterprise annuities reached 3.73 trillion yuan, with a three-year cumulative return of 7.46% [4] - The investment ratio of enterprise annuity funds in A-shares is approximately 14%, indicating significant room for growth towards the 40% cap [4] Group 5 - Huazhong University of Science and Technology has opened the first brain-computer interface outpatient clinic in Central China, providing assessments and consultations for patients [5] - The brain-computer interface industry is expected to experience rapid growth, driven by policy support and technological advancements [5] Group 6 - Haidilao's Hong Kong IPO was highly successful, with a subscription amount reaching nearly 400 billion HKD, oversubscribed by approximately 695 times [7] - The company plans to fully exercise its over-allotment option, increasing the total fundraising amount to about 101.5 billion HKD [7] Group 7 - Midea Group announced a share repurchase plan with a budget of up to 10 billion yuan, aimed at reducing registered capital and implementing employee stock ownership plans [8] - The company has been active in share repurchases, with total plans reaching up to 37 billion yuan since 2021 [8] Group 8 - The "post-exam economy" is gaining traction as graduation travel demand increases, with various scenic spots offering discounts to students [9] - This trend is expected to boost related industries such as dining, accommodation, and transportation, creating more job opportunities [9] Group 9 - In June, brokerage firms conducted 1,576 research activities on 350 listed companies, with a focus on business expansion and international strategies [10] - Yanjing Beer was the most researched company, receiving inquiries from 38 brokerage firms [10] Group 10 - The popularity of trendy toys has surged, with companies like Worth Buying and Qingmu Technology actively engaging in the sector [11] - Worth Buying noted that while they have products related to trendy toys, their contribution to overall revenue is currently low [11]

Core Viewpoint - The integration of chemical and biological synthesis is essential for achieving efficient chemical bond activation, cleavage, and reorganization, emphasizing the collaborative potential of both methods [2][4]. Group 1: Chemical and Biological Synthesis - The core goal of chemical-biological synergy is to enhance efficiency and reduce costs by leveraging the strengths of both chemical and biological synthesis methods [2][4]. - Chemical synthesis will not be completely replaced by biological synthesis; instead, the focus is on how to complement each other to create lower-cost and higher-value pathways [4][5]. Group 2: Case Studies and Applications - Examples include the production of artemisinin, where biological synthesis converts sugars to artemisinic acid, while chemical methods enhance production efficiency through hydrogenation and oxidation [6]. - Collaborative efforts in various fields, such as polymer materials and drug development, have shown significant results, indicating a broad application prospect for chemical-biological synergy [6]. Group 3: Advances in Catalysis - Biomimetic catalysis is a key area where chemists learn from biologists, with future developments focusing on the diversity of catalytic systems and synergistic catalytic functions [7]. - Breakthroughs in artificial enzymes and non-natural reactions have been achieved by combining chemical catalysts with protein systems, providing new pathways for complex molecule synthesis [8]. Group 4: Innovations in Synthetic Biology - Combinatorial biosynthesis through genome recombination and editing generates non-natural products, with chemical methods playing a crucial role in precursor provision and subsequent modifications [9]. - The synthesis of nucleic acids, proteins, and carbohydrates faces challenges, but advancements are being made in functionalization and long DNA synthesis [11][12][13]. Group 5: Future Outlook and Technological Integration - AI and big data are poised to play significant roles in promoting the integration of chemical and biological synthesis, accelerating genome mining, molecular design, and synthesis pathway optimization [14]. - The deep-sea scientific program exemplifies the potential for protein and enzyme modification in extreme environments, showcasing innovative research directions [15]. Group 6: Policy and Support for Research - A call for national-level top-level design to promote interdisciplinary research in chemical-biological synergy, particularly supporting young researchers in fields like medicine, materials, energy, and carbon neutrality [16].

Core Viewpoint - The Ministry of Industry and Information Technology and the National Development and Reform Commission have issued a notice to cultivate pilot-scale biomanufacturing platforms, aiming to establish over 20 platforms and serve more than 200 enterprises by 2027, with the goal of incubating over 400 products [1][2][3]. Group 1: Cultivation Areas - The initiative focuses on addressing the shortcomings and pain points in the pilot-scale phase of biomanufacturing, targeting key product areas such as food and additives, biopharmaceuticals, cosmetics, chemicals, energy, and enzyme preparations [5]. - Emphasis will be placed on developing pilot platforms for new raw materials in biomanufacturing, particularly lignocellulosic materials and one-carbon compounds (e.g., carbon monoxide, methanol) [5]. - The program will also support the establishment of pilot platforms for plant chassis cells, which utilize genetically modified plant cells (such as tobacco, rice, and Taxus cells) to fill gaps in emerging fields [5].